190 related articles for article (PubMed ID: 30871800)
1. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
[TBL] [Abstract][Full Text] [Related]
2. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
Eleopra R; Tugnoli V; Quatrale R; Gastaldo E; Rossetto O; De Grandis D; Montecucco C
Clin Neurophysiol; 2002 Aug; 113(8):1258-64. PubMed ID: 12140005
[TBL] [Abstract][Full Text] [Related]
3. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
4. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.
Eleopra R; Tugnoli V; Rossetto O; De Grandis D; Montecucco C
Neurosci Lett; 1998 Nov; 256(3):135-8. PubMed ID: 9855358
[TBL] [Abstract][Full Text] [Related]
5. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study.
Eleopra R; Montecucco C; Devigili G; Lettieri C; Rinaldo S; Verriello L; Pirazzini M; Caccin P; Rossetto O
Clin Neurophysiol; 2013 May; 124(5):999-1004. PubMed ID: 23245668
[TBL] [Abstract][Full Text] [Related]
6. BoNT/AB hybrid maintains similar duration of paresis as BoNT/A wild-type in murine running wheel assay.
Kutschenko A; Reinert MC; Krez N; Liebetanz D; Rummel A
Neurotoxicology; 2017 Mar; 59():1-8. PubMed ID: 28043867
[TBL] [Abstract][Full Text] [Related]
7. The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products.
Kutschenko A; Bigalke H; Wegner F; Wohlfarth K
Toxicon; 2019 Oct; 168():158-163. PubMed ID: 31323228
[TBL] [Abstract][Full Text] [Related]
8. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
9. A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
Donald S; Elliott M; Gray B; Hornby F; Lewandowska A; Marlin S; Favre-Guilmard C; Périer C; Cornet S; Kalinichev M; Krupp J; Fonfria E
Pharmacol Res Perspect; 2018 Dec; 6(6):e00446. PubMed ID: 30519475
[TBL] [Abstract][Full Text] [Related]
10. Different types of botulinum toxin in humans.
Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin: application, safety, and limitations.
Bigalke H
Curr Top Microbiol Immunol; 2013; 364():307-17. PubMed ID: 23239359
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Morbiato L; Carli L; Johnson EA; Montecucco C; Molgó J; Rossetto O
Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
[TBL] [Abstract][Full Text] [Related]
13. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A.
Kerscher M; Wanitphakdeedecha R; Trindade de Almeida A; Maas C; Frevert J
J Drugs Dermatol; 2019 Jan; 18(1):52-57. PubMed ID: 30681794
[TBL] [Abstract][Full Text] [Related]
14. Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN).
Bigalke H; Rummel A
Toxins (Basel); 2015 Nov; 7(12):4895-905. PubMed ID: 26610569
[TBL] [Abstract][Full Text] [Related]
15. Does the guidance method affect the doses of botulinum toxin in writer's cramp?
Kreisler A; Watel K; Defebvre L; Mortain L; Duhamel A
Rev Neurol (Paris); 2024 Jun; 180(6):548-558. PubMed ID: 38336523
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report.
Hefter H; Beek J; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34203875
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a.
Thyagarajan B; Krivitskaya N; Potian JG; Hognason K; Garcia CC; McArdle JJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):361-71. PubMed ID: 19654265
[TBL] [Abstract][Full Text] [Related]
18. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.
Roger Aoki K
Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646
[TBL] [Abstract][Full Text] [Related]
19. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
Caleo M; Spinelli M; Colosimo F; Matak I; Rossetto O; Lackovic Z; Restani L
J Neurosci; 2018 Nov; 38(48):10329-10337. PubMed ID: 30315128
[TBL] [Abstract][Full Text] [Related]
20. Clinical duration of action of different botulinum toxin types in humans.
Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
